Abbott Laboratories is a medical device company located in Illinois, United States, which is part of the Healthcare sector, and is traded under the ticker ABT on the NYSE exchange.
Abbott Laboratories stock last closed at $124.67, up 0.19% from the previous day, and has increased 8.93% in one year. It has overperformed other stocks in the Medical Devices industry by 0.44 percentage points. Abbott Laboratories stock is currently +12.46% from its 52-week low of $110.86, and -11.73% from its 52-week high of $141.23.
There are currently 1.74B shares of ABT outstanding. The market cap of ABT is $216.79B. In the past 24 hours, 4.88M ABT shares were traded.
You will need a brokerage account to access the NYSE market and buy ABT shares.
 Our recommended brokerage: eToro
Our recommended brokerage: eToroIn our opinion, eToro is the best place to buy stocks. Here's why:
Get $10 towards your purchase of shares by opening an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've selected your brokerage, you'll need to fill out some personal details so you are able to invest in ABT stock today.
Now that you have created your account on our top ranked stock market app, you can securely and quickly fund your account:
Watch the walkthrough below for more details transferring money into your brokerage account.
After you have selected the best place to buy Abbott Laboratories stock, it's important to research their stock prior to investing, so you truly understand the risk as well as the opportunity.
WallStreetZen was built to help part-time investors do more in-depth fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on ABT's stock page.
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge ABT's fair value.
Using relative valuations metrics:
You can access more valuation research on ABT's stock here.
Out of 12 Equities analysts who track ABT, the consensus analyst rating on ABT is a Strong Buy
Please note that analyst ratings are not stock recommendations, nor are they financial advice.
Marie Thibault, a top 16% analyst from BTIG reiterates ABT with a strong buy rating and maintains their ABT price target from $145.00 to $145.00, on Oct 15, 2025.
Bruce Jackson, a bottom 1% analyst from Benchmark initiates coverage on ABT with a strong buy rating and announces their ABT price target of $145.00, on Oct 10, 2025.
Joanne Wuensch, a top 8% analyst from Citigroup maintains ABT with a strong buy rating and lowers their ABT price target from $157.00 to $155.00, on Jul 18, 2025.
Anthony Petrone, a top 6% analyst from Mizuho maintains ABT with a hold rating and lowers their ABT price target from $140.00 to $135.00, on Jul 18, 2025.
Matthew Taylor, a top 15% analyst from Jefferies upgrades ABT to a strong buy rating and raises their ABT price target from $143.00 to $145.00, on Jul 18, 2025.
Jefferies's Matthew Taylor upgraded their rating on Abbott Laboratories (NYSE: ABT) from Hold to Strong Buy on 2025/07/18. The analyst also raised their price target by 1.4% from $143 to $145.
Abbott Laboratories reported its Q2 2025 earnings.
Taylor upgraded the stock and hiked their price target in response.
Acknowledging that the quarter's results and management's guidance were "underwhelming," the analyst argued that the post-print dip was "too punitive," and recommended that readers take advantage of the pullback because Abbott Laboratories' growth can accelerate in 2026.
Taylor detailed that the stock's current valuation is "compelling for a quality franchise with multiple growth drivers."
For Q2 2025, Abbott Laboratories reported:
Management guided:
For Q3 2025:
For FY 2025:
Chairman & CEO Robert B. Ford commented: "Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new
product pipeline.
"We see this momentum carrying into 2026."
You can dig deeper into what analysts are forecasting on the Abbott Laboratories stock forecast page.
Last year, ABT earnings were $13.98B. During the last five year, ABT's earnings have gone up by 33.31% per year. This was faster than the Medical Devices industry average of 18.74%.
Last year, ABT revenue was $43.84B. Over the last five year, ABT's revenue has grown by 6.35% per year. This was slower than the Medical Devices industry average of 10.66%.
You can analyze ABT's earnings and revenue performance here.
In the last 12 months, insiders at ABT have sold more shares than they have bought.
Philip P. Boudreau, EVP AND CFO of ABT, was the latest ABT insider to sell. They sold $51,339.42 worth of ABT shares on Sep 1, 2025.
Learn more about who owns ABT stock here.
Abbott Laboratories pays a dividend of 1.42%, compared to the Medical Devices industry's average dividend yield of 1.03%. If you owned $1,000 of ABT stock, you would have been paid $14.20 last year.
Abbott Laboratories dividend payments have consistently grown over the past decade and have remained stable.
Find more analysis about Abbott Laboratories dividend yield and history here.
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other traders have to say.
You have two primary order types:
Click the Open Trade button and your broker will place your order.
If you need more help with buying stocks on eToro, click the helpful video below:
Now that you own some shares in ABT, you'll want to stay up-to-date on your company.
Start a watchlist to get notified of the latest news about your ABT stock.
To reiterate, here are the 6 steps to buy stock in Abbott Laboratories:
If you are looking for a brokerage account, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to get the latest scoop on your investment in Abbott Laboratories, click below.